Rebiotix®

KEY MILESTONES IN HARNESSING THE POWER OF HUMAN MICROBIOME

2011
- Rebiotix was founded with $5M Series A round fundraising

2012
- Pre-Investigational New Drug (IND) meeting with FDA for RBX2660

2013
- FDA IND granted
- Fast Track designation granted
- PUNCH CD phase 2 trial enrolled for RBX2660 to treat recurrent Clostridium difficile

2014
- $25M Series B round fundraising completed
- FDA Orphan Drug designation granted
- Results of PUNCH CD announced
- PUNCH CD 2 (phase 2b) trial initiated
- Development of oral formulation, RBX7455, started

2015
- PUNCH CD 2 enrollment for RBX2660 completed
- FDA Breakthrough Status granted for RBX2660
- Oral formulation Drug Master File (DMF) filed with FDA